// App-Quantinova.ai

BSH2020‐EP‐089 : A single centre experience of using ciclosporin and mycophenolate mofetil immunosuppression in relapsed/refractory angio‐immunoblastic T‐cell lymphoma

Researchers

Presenter

  • K. De Abrew

Principal Investigators

  • J. Howells

  • R. Corser

  • R. Ayto

  • A. O'Callaghan

Medical Centers

  • Queen Alexandra Hospital, Portsmouth, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Nephrology

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Autoimmune hemolytic anemia

  • Renal insufficiency

  • T-cell lymphoma

  • Nephrotoxicity

  • Lymphomas

Biomarkers

  • 18F-fluorodeoxyglucose

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Mycophenolic acid

  • Lenalidomide

  • Methotrexate

  • Cyclosporine A

  • Gemcitabine

  • Cisplatin

  • Rituximab

  • Florid

  • IVIG

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved